Literature DB >> 2065041

Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro.

S Björkerud1.   

Abstract

Control of the thickness of the arterial wall is critical, as excessive overgrowth of constituent smooth muscle cells (SMCs) may interfere with blood flow. Effects on SMCs in vitro of several growth factors that are present in blood and/or that are produced endogenously in the arterial wall under certain conditions suggest that influences of endocrine, paracrine, and autocrine nature from stimulating and inhibiting factors may control the smooth muscle tissue mass in the artery. This possibility was explored further by investigating the degree of myodifferentiation in terms of the presence of differentiation-specific filamentous alpha-smooth muscle actin and growth, as measured by the synthesis of DNA and cell number, of SMCs as influenced by their exposure to the mitogens, platelet-derived growth factor and epidermal growth factor, and the bifunctional growth factor, transforming growth factor-beta 1 (TGF-beta 1). Exposure to TGF-beta 1 markedly enhanced differentiation-specific filamentous alpha-smooth muscle actin. This effect did not require arrest of growth, which speaks against a direct causal relation between loss of myodifferentiation (modulation) and multiplication. When quiescent cultures were exposed to TGF-beta 1, alpha-smooth muscle actin was further increased, indicating a more specific differentiation-promoting effect by TGF-beta 1 than mere inhibition of growth. Exposure to TGF-beta 1 also increased spreading, which occurred in parallel with increased filamentous alpha-smooth muscle actin and appearance of stress fibers. Exposure to platelet-derived growth factor under serum-free conditions and to epidermal growth factor in cultures exposed to serum markedly decreased the number of alpha-actin-positive SMCs, indicating a dedifferentiating effect by these mitogens. Exposure of SMCs to TGF-beta 1 under serum-free conditions had pronounced effects on growth, with a concentration-dependent inhibition of platelet-derived growth factor-induced DNA synthesis and cell multiplication. The basal synthesis of DNA in the absence of added growth factors was also greatly inhibited. With serum-free cultures, some loss of cells occurred even with very low concentrations of TGF-beta 1 (5 pg/ml), against which platelet-derived growth factor or a dense cultural state had a protective effect. Enhancement of cell multiplication was not detected for cultivated human SMCs exposed to TGF-beta 1, irrespective of culture density, in contrast to that reported for dense cultures of rat SMCs. TGF-beta 1 is present in and may be released from platelets in situations that promote platelet adherence such as endothelial injury; TGF-beta 1 may also be released from activated macrophages and T lymphocytes either during an immune reaction or inflammation or from the endothelium.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065041

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  45 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

3.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

Authors:  G H Gibbons; R E Pratt; V J Dzau
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Expression of V3 Versican by Rat Arterial Smooth Muscle Cells Promotes Differentiated and Anti-inflammatory Phenotypes.

Authors:  Inkyung Kang; Jeremy L Barth; Erin P Sproul; Dong Won Yoon; Gail A Workman; Kathleen R Braun; W Scott Argraves; Thomas N Wight
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

5.  Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism.

Authors:  Ashfaque A Memon; Kristina Sundquist; Xiao Wang; Peter J Svensson; Jan Sundquist; Bengt Zöller
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 6.  Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects.

Authors:  Ian Toma; Timothy A McCaffrey
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

7.  TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin.

Authors:  A Berndt; H Kosmehl; U Mandel; U Gabler; X Luo; D Celeda; L Zardi; D Katenkamp
Journal:  Histochem J       Date:  1995-12

8.  VE-statin, an endothelial repressor of smooth muscle cell migration.

Authors:  Fabrice Soncin; Virginie Mattot; Frédéric Lionneton; Nathalie Spruyt; Frédéric Lepretre; Agnès Begue; Dominique Stehelin
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

9.  Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice.

Authors:  Jie Hong Hu; Hao Wei; Mia Jaffe; Nathan Airhart; Liang Du; Stoyan N Angelov; James Yan; Julie K Allen; Inkyung Kang; Thomas N Wight; Kate Fox; Alexandra Smith; Rachel Enstrom; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-22       Impact factor: 8.311

10.  Loss of microRNA-17∼92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5.

Authors:  Tianji Chen; Guofei Zhou; Qiyuan Zhou; Haiyang Tang; Joyce Christina F Ibe; Hongqiang Cheng; Deming Gou; Ju Chen; Jason X-J Yuan; J Usha Raj
Journal:  Am J Respir Crit Care Med       Date:  2015-03-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.